Instead of pushing to the full weight-loss dose, some patients start at a low dose, just enough to nudge the metabolic and inflammatory pathways, without major appetite suppression
Although several different clinical trial designs have been employed, 2,3,4 the most common and straightforward methodology to test a promising disease modifying therapy is to assess its ability to slow progression of clinical signs and symptoms versus placebo over time in patients with early PD while they are not receiving symptomatic PD medications (e.g., levodopa, dopamine agonists, MAO-B inhibitors)
We want to keep the long-term perspective in mind and how healthy will I be in one year or five years, not just in six months
g No statistical significance but no data provided in detail
Her nausea dropped by 50%